Navigation Links
Early Indicator of Kidney Disease May Also Predict Risk of Pre-Diabetes

involved 1,455 of the original participants, all of whom had no known heart or kidney disease. Information on health indicators were collected once again. Analysis determined that 91 people who had normal glucose levels in 1996 had developed pre-diabetes since then.

Levels of cystatin C then were measured in the blood samples taken at baseline of these 91 and were compared to cystatin C levels in samples from 273 participants from the original cohort who had not developed pre-diabetes.

Results showed a direct link between those with the highest levels of cystatin C and the development of pre-diabetes, said Donahue. The association didn't change when factors that traditionally are related to development of diabetes such as weight, amount of blood glucose at baseline, smoking history, high blood pressure or alcohol use were considered, he noted.

"Pre-clinical signs of renal impairment may occur before or coincident with pre-diabetes," Donahue said. "These findings may suggest that those who have pre-diabetes also should be screened for early signs of kidney impairment, which itself is a major chronic illness and cause of much morbidity and mortality."

The study was supported by a grant to Donahue from the National Institute of Diabetes and Digestive and Kidney Diseases.


'"/>




Page: 1 2

Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
(Date:5/9/2008)...nversion achieves technology and sensor standardiz...d reduces costs, IRVINE, Calif., May 9 /PRNewswir...Masimo, the inventor of Pulse CO-Oximetry and,Meas...y, have announced the,completion of Saint Barnabas...Masimo SET pulse oximetry. The New Jersey-based ho...
(Date:5/9/2008)...Calif., May 9 /PRNewswire/ -- Claremont Insurance,... Cyntron Payroll Solutions,( http://www.cyntron.co...arket and sell payroll services through the employ...the selling power and service capability of,employ...urring revenue,stream for the broker and protectio...
(Date:5/9/2008)...y 9 /PRNewswire/ -- The U.S. Air Force has paid a ... by a baby during childbirth at,a military hospita...ement,payments to children who suffered brain dama...es, according to what Air Force attorneys told the...n September 4, 2004 at the U.S. Naval,Hospital, Ok...
(Date:5/9/2008)...Calif., May 9 /PRNewswire/ -- Dakim, Inc., announc...d,s most iconic figure in,health and fitness, has ...on behalf of the company,s [m]Power Cognitive Fitn...seniors fight against dementia., Dakim,s [m]Power...igned,to help seniors combat a decline in mental f...
Breaking Medicine News(10 mins):Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 2Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 3Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 4Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 5Health News:New Payroll Service Expands Selling Power and Service Capability of Employee Benefits Brokers 2Health News:U.S. Air Force Pays Record Amount for Baby Injured in Government Hospital 2Health News:Physical Fitness 'Godfather' Jack LaLanne Turns to Brain Fitness, Becoming Ambassador for Dakim's [m]Power System 2
...patented the technology of making new transgenic m...ooms for the mass production of commercially valua...gy was introduced by a team of researchers includi...e and Xi Chen at Penn State. As part of the study...
...the other from Bangalore -- are among the winners ... Saji Das from Biotech in Kerala was the first pr...ds) for developing and installing biogas plants in... often left out in the streets to rot, to generate...
...riday welcomed the European Union (EU) Parliament'...ironmental pollution, and urged the Indian governm...groups hailed the EU resolution on Wednesday. The...governments across the world to ban import of merc...
...ressions of insect love and desire. The cicada's s...es of how an emitting sex attracts conspecific me...es), though less conspicuous for us humans, are al...them, even on the darkest nights. Such mating reco...
Other Medicine News:Health News:New Transgenic Mushrooms Raise Hope for Mass Production of Human Drugs 2Health News:Indian Projects Win Top Ashden Awards 2Health News:Another Sexual Attraction is Possible ... 2
(Date:5/8/2008)...rstCall/ -- AstraZeneca (NYSE:,AZN) today announce...ation,(sNDA) to the U.S. Food and Drug Administrat...) Extended-Release Tablets to seek approval for th... including maintenance of,antianxiety effect. It i...typical antipsychotic medicine in GAD. The submiss...
(Date:5/7/2008).../ -- Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) ...d.,initiated a Phase 1 clinical trial of a drug ca...a to develop compounds to treat psychiatric disord...ntended for the treatment of a,common psychiatric ...nding partner, Taisho,effectively continue its ef...
(Date:5/7/2008)...-FirstCall/ -- Johnson & Johnson,will provide a pr...y, May 9,at 4:00 p.m. (Eastern Time) to coincide w...ng in Tampa, Fla. Phase 3 clinical data presentati...e (IR), a novel centrally acting,oral analgesic, w...e-recorded Webcast, with the lead tapentadol resea...
(Date:5/6/2008)...Individualized Treatment for ...re-FirstCall/ -- Data presented today on,Vanda Pha...al drug candidate,iloperidone, included its 4-wee... analysis of three long-term, 52-week trials, stud...ridone is a 5HT2/D2 antagonist ("atypical"),antips...
Breaking Medicine Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 2Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 3Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 4Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 5Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 6Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 7STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 9642 1STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 9642 2STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 9642 3Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2DNA Analysis Could Help Customize Treatments for MS 9638 1DNA Analysis Could Help Customize Treatments for MS 9638 2Evolution of human genomes guardian gives people unique protections from DNA damage 9634 1Evolution of human genomes guardian gives people unique protections from DNA damage 9634 2Evolution of human genomes guardian gives people unique protections from DNA damage 9634 3Evolution of human genomes guardian gives people unique protections from DNA damage 9634 4
...ivative compound series show highly,selective PI...,treatment , , QUBEC CITY, Canada, April,16...EZS), a global, pure play biopharmaceutical compan...ay presented an abstract,outlining first in vitr...gh selectivity for PI3K inhibition, at the America...
... Cougar Biotechnology,Inc. (OTCBB:CGRB) today ann...the Company,s prostate cancer drug candidate CB763...can Association for,Cancer Research (AACR) Annual ...resented in two oral presentations as part of a,sp...king Clinical,Trials. These presentations are furt...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 2Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 3Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 4Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 5
ELISA kit for Varicella-zoster IgG.
Inquire
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma.
...ntific Corporation announced the launch of the Ch...bi-directional cooled-tip catheter available in th...ysicians the benefits of cooled ablation technolog...n Scientific Blazer(R) catheter platform. ,Coole...
Medicine Products: